FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999762017> ?p ?o ?g. }

• W1999762017 abstract "Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DCBackground: Deciphering acquired mechanisms of resistance to sunitinib, a multitarget receptor tyrosine kinase inhibitors blocking VEGFR, PDGFR, KIT, and RET, remains a major clinical challenge for developing a second generation of compounds, simultaneous and sequential combination strategies. This study aimed characterizing molecular changes associated with acquired cellular resistance to sunitinib in two human cancer models.Materials and Methods: Parental MCF7 breast carcinoma and SK-HEP1 hepatocellular carcinoma cells primarily sensitive to sunitinib were exposed to stepwise increasing doses of sunitinib for >4 months and >7 months, respectively. MCF7-suni and SK-HEP1-suni were shown to grow in the presence of 3-fold IC50 concentrations as compared to parental cells. Mouse xenograft bearing MCF7 were treated with subtoxic doses of sunitinib 2-20mg/kg/day. mRNA levels of a panel of 75 selected genes were evaluated in sensitive and resistant cell lines using q-RT-PCR. Protein phoshorylation (p) was assessed by western-blot analysis.Results: MCF-7 cells expressed PDGFRA and SK-HEP1 cells expressed PDGFRB, both having low/no baseline levels of VEGFR1-3 and RET mRNA expression. Exposure to 48-hour sunitinib led to IC50s of 5.5µM and 4.5µM in MCF-7 and SK-HEP1, respectively. In SK-HEP1 cells, exposure to sunitinib was associated with a decreased p-AKTS473, p-70S6KT389 and p-ERKT202/Y204. IC50s of sunitinib were 10µM in MCF7-suni and 11 µM in SK-HEP1-suni. Sustained exposure to sunitinib led to >3-fold increased mRNA expression of VEGFC, VEGFR1, VEGFR3, Neuropilin-1, CXCL12, CXCR4, HIF1-alpha, PDGFRA, endothelin-1, RET, and in a lesser extend EG-VEGF in MCF7-suni as compared to parental MCF7. Protracted exposure to sunitinib in SK-HEP1-suni led to a >3-fold increase mRNA expression of VEGFA-D, VEGFR3, CXCL12, CXCR4, PDGFRA, and RET as compared to parental SK-HEP1 cells. At IC50 concentration, p-ERKT202/Y204 was decreased in SK-HEP1-suni cells. To mimic acquired resistance to sunitinib in human, mice bearing MCF7 xenografts were treated using continuous daily dosing of sunitinib until occurrence of tumor progression under therapy occurring around day 20. mRNA expressions were compared in tumors at baseline and at the time of progression. Increased >3-fold mRNA expressions of CXCR4, CXCL12, PDGFRA were observed in progressive xenograft as compared to untreated control tumors.Conclusions: Our results suggest that acquired in vitro & in vivo resistance of human cancer cells to sunitinib may involve the increased expression of several known targets of sunitinib as well as the expression of other family of receptor involved in tumor angiogenesis, invasion, and metastasis. Further works shall focus in understanding the intriguing role of CXCR4/CXCL12 (SDF-1) in the development of resistance to sunitinib.Partially granted by FNAB.Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 366." @default.
• W1999762017 created "2016-06-24" @default.
• W1999762017 creator A5002864173 @default.
• W1999762017 creator A5003374394 @default.
• W1999762017 creator A5013952219 @default.
• W1999762017 creator A5026162865 @default.
• W1999762017 creator A5035047505 @default.
• W1999762017 creator A5037964830 @default.
• W1999762017 creator A5043109982 @default.
• W1999762017 creator A5053982831 @default.
• W1999762017 creator A5067292546 @default.
• W1999762017 creator A5090530306 @default.
• W1999762017 date "2010-04-15" @default.
• W1999762017 modified "2023-10-14" @default.
• W1999762017 title "Abstract 366: Changes in gene expression profiles in human breast & liver cancer cells and xenografts acquiring resistance to sunitinib" @default.
• W1999762017 doi "https://doi.org/10.1158/1538-7445.am10-366" @default.
• W1999762017 hasPublicationYear "2010" @default.
• W1999762017 type Work @default.
• W1999762017 sameAs 1999762017 @default.
• W1999762017 citedByCount "0" @default.
• W1999762017 crossrefType "proceedings-article" @default.
• W1999762017 hasAuthorship W1999762017A5002864173 @default.
• W1999762017 hasAuthorship W1999762017A5003374394 @default.
• W1999762017 hasAuthorship W1999762017A5013952219 @default.
• W1999762017 hasAuthorship W1999762017A5026162865 @default.
• W1999762017 hasAuthorship W1999762017A5035047505 @default.
• W1999762017 hasAuthorship W1999762017A5037964830 @default.
• W1999762017 hasAuthorship W1999762017A5043109982 @default.
• W1999762017 hasAuthorship W1999762017A5053982831 @default.
• W1999762017 hasAuthorship W1999762017A5067292546 @default.
• W1999762017 hasAuthorship W1999762017A5090530306 @default.
• W1999762017 hasConcept C101544691 @default.
• W1999762017 hasConcept C121608353 @default.
• W1999762017 hasConcept C126322002 @default.
• W1999762017 hasConcept C16930146 @default.
• W1999762017 hasConcept C170493617 @default.
• W1999762017 hasConcept C2775922572 @default.
• W1999762017 hasConcept C2778820342 @default.
• W1999762017 hasConcept C2779490328 @default.
• W1999762017 hasConcept C37307934 @default.
• W1999762017 hasConcept C42362537 @default.
• W1999762017 hasConcept C502942594 @default.
• W1999762017 hasConcept C71924100 @default.
• W1999762017 hasConcept C98274493 @default.
• W1999762017 hasConceptScore W1999762017C101544691 @default.
• W1999762017 hasConceptScore W1999762017C121608353 @default.
• W1999762017 hasConceptScore W1999762017C126322002 @default.
• W1999762017 hasConceptScore W1999762017C16930146 @default.
• W1999762017 hasConceptScore W1999762017C170493617 @default.
• W1999762017 hasConceptScore W1999762017C2775922572 @default.
• W1999762017 hasConceptScore W1999762017C2778820342 @default.
• W1999762017 hasConceptScore W1999762017C2779490328 @default.
• W1999762017 hasConceptScore W1999762017C37307934 @default.
• W1999762017 hasConceptScore W1999762017C42362537 @default.
• W1999762017 hasConceptScore W1999762017C502942594 @default.
• W1999762017 hasConceptScore W1999762017C71924100 @default.
• W1999762017 hasConceptScore W1999762017C98274493 @default.
• W1999762017 hasLocation W19997620171 @default.
• W1999762017 hasOpenAccess W1999762017 @default.
• W1999762017 hasPrimaryLocation W19997620171 @default.
• W1999762017 hasRelatedWork W1548592697 @default.
• W1999762017 hasRelatedWork W1558776379 @default.
• W1999762017 hasRelatedWork W1936603017 @default.
• W1999762017 hasRelatedWork W1993103935 @default.
• W1999762017 hasRelatedWork W2000295132 @default.
• W1999762017 hasRelatedWork W2006143647 @default.
• W1999762017 hasRelatedWork W2009598546 @default.
• W1999762017 hasRelatedWork W2013169601 @default.
• W1999762017 hasRelatedWork W2013210951 @default.
• W1999762017 hasRelatedWork W2029680504 @default.
• W1999762017 hasRelatedWork W2030789369 @default.
• W1999762017 hasRelatedWork W2077346946 @default.
• W1999762017 hasRelatedWork W2079956098 @default.
• W1999762017 hasRelatedWork W2088944779 @default.
• W1999762017 hasRelatedWork W2315073734 @default.
• W1999762017 hasRelatedWork W2317426328 @default.
• W1999762017 hasRelatedWork W2329037707 @default.
• W1999762017 hasRelatedWork W2335564026 @default.
• W1999762017 hasRelatedWork W3030282757 @default.
• W1999762017 hasRelatedWork W3132520529 @default.
• W1999762017 isParatext "false" @default.
• W1999762017 isRetracted "false" @default.
• W1999762017 magId "1999762017" @default.
• W1999762017 workType "article" @default.